Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)
Blood (2022) 140 (Supplement 1): 9871–9872.
Currently there are no citedby results. Try again later.
